{
    "clinical_study": {
        "@rank": "90791", 
        "acronym": "ROPI", 
        "arm_group": [
            {
                "arm_group_label": "DRUG : ROPIVACAINE", 
                "arm_group_type": "Experimental", 
                "description": "20 mL topically used during alginate dressing"
            }, 
            {
                "arm_group_label": "PLACEBO : NaCl 0.9 %", 
                "arm_group_type": "Placebo Comparator", 
                "description": "20 mL topically used during alginate dressing"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of the study is to Evaluate of the analgesic effect of ropivacaine in topical use at\n      the thin skin graft donor site.\n\n      For Patient needing a thin skin graft < 320 cm2, randomization will be done in 2 groups, one\n      receiving the standard treatment (20 mL of physiologic serum) during the surgical\n      intervention in topical use to recover an alginate dressing (Algosteril)and the other\n      receive 20 mL of Naropein during the surgical intervention on alginate dressing.\n\n      The hypothesis of the study is the administration of ropivacaine will decrease the\n      post-operative pain compared to physiologic serum"
        }, 
        "brief_title": "Evaluation of the Analgesic Effect of Ropivacaine in Topical Use at the Thin Skin Graft Donor Site", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Graft Pain", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient older than 18 years old\n\n          -  Patient needing a thin skin graft < 320 cm2 and which is possible on the thigh\n\n          -  Patient who read the information letter and signed  the informed consent\n\n          -  Patient affiliated at a social security system\n\n          -  Effective contraceptive method for more than 3 months for women of childbearing age\n\n        Exclusion Criteria:\n\n          -  Contraindication to one of the medicine used (allergy, intolerance, potential drug\n             interaction)\n\n          -  Treatment by classII or III of analgesics or analgesic dose of aspirin(>500mg per\n             day) at the inclusion or randomization time\n\n          -  Preoperative EVA>0 at the skin graft donor site on the thigh\n\n          -  Sensory disturbances of the lower limbs\n\n          -  Cognitive disturbances not allowing investigations\n\n          -  Pregnant or lactating women\n\n          -  People deprived of discernment\n\n          -  People deprived of their liberty by judicial or administrative authority\n\n          -  Protected adult (guardianship or trusteeship)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "88", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01999153", 
            "org_study_id": "2012/119/HP"
        }, 
        "intervention": [
            {
                "arm_group_label": "DRUG : ROPIVACAINE", 
                "description": "20 mL topically used during alginate dressing", 
                "intervention_name": "20 mL topically used during alginate dressing  NAROPEINE", 
                "intervention_type": "Drug", 
                "other_name": "Brand name of drug use NAROPEINE"
            }, 
            {
                "arm_group_label": "PLACEBO : NaCl 0.9 %", 
                "description": "20 mL topically used during alginate dressing", 
                "intervention_name": "20 mL topically used during alginate dressing NaCl", 
                "intervention_type": "Drug", 
                "other_name": "NaCl 0.9 %"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Alginic acid", 
                "Analgesics", 
                "Ropivacaine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "skin graft", 
            "donor site"
        ], 
        "lastchanged_date": "March 12, 2014", 
        "location": {
            "contact": {
                "email": "dorothee.coquerel-beghin@chu-rouen.fr", 
                "last_name": "doroth\u00e9e COQUEREL-BEGHIN, Md", 
                "phone": "+33232888760"
            }, 
            "facility": {
                "address": {
                    "city": "Rouen", 
                    "country": "France", 
                    "zip": "76031"
                }, 
                "name": "UHRouen"
            }, 
            "investigator": {
                "last_name": "Doroth\u00e9e COQUEREL-BEGHIN, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Evaluation of the Analgesic Effect of Ropivacaine in Topical Use at the Thin Skin Graft Donor Site", 
        "overall_contact": {
            "email": "dorothee.coquerel-beghin@chu-rouen.fr", 
            "last_name": "Doroth\u00e9e COQUEREL, MD", 
            "phone": "+33232888760"
        }, 
        "overall_official": {
            "affiliation": "University Hospital, Rouen", 
            "last_name": "Doroth\u00e9e COQUEREL-BEGHIN, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Evaluate the effect of ropivacaine in topical use on an alginate dressing by evaluating the use of class II analgesic medicines in patient who had a thin skin graft", 
            "measure": "Class II analgesic consumption between the 2 arms", 
            "safety_issue": "No", 
            "time_frame": "5 days post-operative"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01999153"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "evaluate the effect of ropivacaine on postoperative pain at the skin graft donor site", 
                "measure": "Class II antalgic consumption between the 2 arms", 
                "safety_issue": "No", 
                "time_frame": "Day 90"
            }, 
            {
                "description": "potential side effects of ropivacaine on the healing of skin graft donor site", 
                "measure": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "day 90"
            }
        ], 
        "source": "University Hospital, Rouen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital, Rouen", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}